100 related articles for article (PubMed ID: 4006048)
1. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.
Buck M; Kovach JS
Cancer Chemother Pharmacol; 1985; 15(1):40-3. PubMed ID: 4006048
[TBL] [Abstract][Full Text] [Related]
2. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro metabolism of the new anticancer drug bisantrene.
Peng YM; Alberts DS; Davis TP
Cancer Chemother Pharmacol; 1985; 14(1):15-20. PubMed ID: 3965156
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
5. Regional targeting of bisantrene by directed intravascular precipitation.
Kovach JS; Buck M; Tsukamoto T; Odegaard A; Lieber MM
Cancer Chemother Pharmacol; 1985; 15(3):192-5. PubMed ID: 4053264
[TBL] [Abstract][Full Text] [Related]
6. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid.
Davis TP; Peng YM; Goodman GE; Alberts DS
J Chromatogr Sci; 1982 Nov; 20(11):511-6. PubMed ID: 6960001
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
8. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
9. Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone.
Peng YM; Ormberg D; Alberts DS; Davis TP
J Chromatogr; 1982 Dec; 233():235-47. PubMed ID: 7161336
[TBL] [Abstract][Full Text] [Related]
10. Tissue deposition of bisantrene in B16 melanoma tumor-bearing mice.
Nicolau G; Wu WH; McWilliams W; Citarella RV; Durr FE
Cancer Invest; 1986; 4(1):25-8. PubMed ID: 3955418
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
12. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies.
Lieber MM; Welch TJ; Johnson CM; Farrow GM; Buck M; Kovach JS
Mayo Clin Proc; 1986 Mar; 61(3):173-9. PubMed ID: 3945117
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
14. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.
Aksentijevich I; Cardarelli CO; Pastan I; Gottesman MM
Clin Cancer Res; 1996 Jun; 2(6):973-80. PubMed ID: 9816258
[TBL] [Abstract][Full Text] [Related]
15. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
16. Interaction of bisantrene anti-cancer agents with DNA: footprinting, structural requirements for DNA unwinding, kinetics and mechanism of binding and correlation of structural and kinetic parameters with anti-cancer activity.
Elliott JA; Wilson WD; Shea RG; Hartley JA; Reszka K; Lown JW
Anticancer Drug Des; 1989 Mar; 3(4):271-82. PubMed ID: 2539168
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.
Visani G; Rizzi S; Tosi P; Cenacchi A; Gamberi B; Lemoli RM; Papadopulu P; Tura S
Haematologica; 1990; 75(6):527-31. PubMed ID: 2098293
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene.
Polverini PJ; Novak RF
Biochem Biophys Res Commun; 1986 Nov; 140(3):901-7. PubMed ID: 2430572
[TBL] [Abstract][Full Text] [Related]
19. [Plasma levels and tissue concentrations in rabbits following cutaneous administration of an indomethacin solution].
Nowack H; Zeiller P; Steck K
Arzneimittelforschung; 1987 Apr; 37(4):432-4. PubMed ID: 3606698
[TBL] [Abstract][Full Text] [Related]
20. Bisantrene, biological and clinical effects.
Coltman CA; Osborne CK
Cancer Treat Rev; 1984 Dec; 11(4):285-8. PubMed ID: 6534510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
